Semax: The Nootropic Peptide That Amplifies BDNF and Protects the Brain

At a Glance

Semax sits in an unusual position in peptide medicine: it has a genuine decades-long clinical track record in one country while remaining largely unknown in Western integrative practice. Developed at the Institute of Molecular Genetics in Moscow during the 1980s, it was registered as a pharmaceutical in Russia in 1991 and has since accumulated a meaningful body of clinical and preclinical literature — the vast majority of which never made it into English-language journals.

The patients who most often ask me about Semax have post-infectious brain fog (particularly after Lyme disease or COVID-19), documented low BDNF, or are recovering from cerebrovascular events. My read is that its mechanism is genuinely interesting for these groups, but outside Russia it remains an unapproved compound, and it never replaces foundational neurology or psychiatry care.

What Is Semax and Where Does It Come From?

Semax is a heptapeptide — seven amino acids — with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was engineered as a stable analog of the ACTH 4–7 tetrapeptide fragment (Met-Glu-His-Phe), which was already known to influence learning and memory in rodent models. The addition of Pro-Gly-Pro at the C-terminus dramatically extends its metabolic stability without adding the adrenocorticotropic activity of the full ACTH hormone.

This distinction matters clinically. Full ACTH stimulates cortisol release from the adrenal glands. Semax does not — it acts centrally on the nervous system without triggering HPA axis activation, which makes it fundamentally different from corticosteroid-based interventions.

The Russian pharmaceutical formulation ships as 0.1% nasal drops (1 mg/mL) in a dropper bottle. According to the Russian label, each drop contains 50 mcg, which makes dosing and titration simple. The intranasal route exploits olfactory neuron transport pathways to bypass the blood-brain barrier, with peak CSF concentrations appearing within 20–30 minutes.

Mechanism of Action: BDNF, Dopamine, and the Glial Response

Semax’s most clinically important mechanism is its upregulation of brain-derived neurotrophic factor (BDNF) and its high-affinity receptor TrkB. BDNF is the primary survival and plasticity signal for neurons in the hippocampus, prefrontal cortex, and brainstem. Chronically low BDNF is associated with depression, cognitive decline, treatment-resistant fatigue, and accelerated neurodegeneration.

Dolotov et al. (2006) found that a single application of Semax (50 mcg/kg) in rats raised hippocampal BDNF protein up to 1.4-fold and BDNF (exon III) mRNA 3-fold. TrkB mRNA doubled and trkB phosphorylation rose 1.6-fold, so the receptor side of the pathway was activated as well, and the treated rats learned an avoidance task better.

Beyond BDNF, Semax influences several other neurochemical systems:

Dopaminergic tone. In rodents, Semax on its own did not change striatal dopamine or its metabolites, but given before amphetamine it markedly increased the amphetamine-induced dopamine release and locomotor activity (Eremin et al., 2005). That points to a modulating effect on dopamine signalling, which is relevant for motivation, executive function and working memory. Patients frequently describe improved mental drive rather than simple stimulation. The effect is qualitatively different from caffeine or amphetamine-class compounds.

Serotonergic modulation. In the same rodent study, the serotonin metabolite 5-HIAA in the striatum rose by 25% in tissue and up to 180% extracellularly within 1-4 hours (Eremin et al., 2005). Semax appears to modulate serotonergic activity, which may partly explain the anxiolytic and mood-stabilizing effects reported anecdotally and in some small clinical series. In patients with chronic infections and significant neuroinflammation, mood dysregulation often tracks BDNF; Semax seems to address both simultaneously.

Inflammatory gene response. In a rat model of transient cerebral ischaemia, ischaemia switched on many pro-inflammatory genes and Semax suppressed their induction, including transcripts such as Il1b, Il6 and Tnfa (Dergunova et al., 2021). In glial cell cultures, Semax rapidly raised neurotrophin mRNAs (Shadrina et al., 2001). This anti-inflammatory signature in animal models is part of why Semax draws interest for post-infectious brain states; it has not been measured in people.

Clinical Evidence: Stroke, TBI, and Cognitive Impairment

The strongest clinical evidence for Semax comes from Russian academic centers studying acute ischemic stroke and its aftermath. In a Moscow study of acute hemispheric ischaemic stroke, 30 patients received Semax on top of standard intensive therapy and were compared with 80 patients of similar stroke severity on standard therapy alone (no placebo). Neurological deficits, especially motor deficits, regressed somewhat faster with Semax; the most effective daily doses were 12 mg for moderate and 18 mg for severe strokes, over 5-10 days (Gusev et al., 1997). A 2018 study in 110 patients after ischaemic stroke reported higher plasma BDNF and faster gains in Barthel index and motor scores with two 10-day Semax courses during rehabilitation (Gusev et al., 2018).

The Russian label also lists conditions after traumatic brain injury among its indications, but I could not find a controlled TBI trial of Semax indexed in PubMed.

For cognitive impairment not caused by acute events — the more common scenario in integrative medicine — the evidence is thinner but directionally consistent. Open-label series from neurological clinics in St. Petersburg and Moscow document improvements in processing speed, verbal memory, and subjective cognitive clarity in patients with age-related cognitive decline and post-encephalitic syndromes.

What the trial literature does not offer, in most cases, is large randomized placebo-controlled data by Western regulatory standards. This is the honest caveat. The mechanistic rationale is solid, the human safety data is reassuring, and the Russian clinical experience is extensive — but Semax has not undergone Phase III RCTs by EMA or FDA criteria.

Semax Variants: Standard, NA-Semax, and the Amidate Form

Three versions circulate, and they are not equivalent. Products sold as “research use only” are not approved or tested for human use, whatever the label says.

Semax (standard): The original 0.1% pharmaceutical formulation. Most clinical data comes from this variant. Appropriate for most people as a starting point.

NA-Semax (N-Acetyl Semax): The acetylated form is claimed to have a longer half-life and a somewhat more potent BDNF effect; I could not find a published comparison with standard Semax to confirm this. The trade-off is that it is more stimulating — people sensitive to dopaminergic activation may find it anxiety-inducing at standard doses. The usual approach is to start at half the standard dose when switching to this variant. It has essentially no human trial data.

NA-Semax Amidate: Both acetylated and C-terminally amidated, which theoretically further extends metabolic stability and potency. The least amount of human data exists for this form. It is generally reserved for people who have already established tolerability with standard Semax and are seeking incremental gains, not used as a first choice.

For clinical purposes, standard Semax at 300–600 mcg/day intranasally is the usual starting point and where most people remain.

Dosing Protocol and Cycling

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Intranasal (standard clinical approach):

• Start: 100–200 mcg once daily (1–2 drops per nostril), typically in the morning
• Titrate to 300–600 mcg/day over 5–7 days if tolerated
• Some people benefit from a second dose before cognitively demanding work, not after 2pm (to avoid sleep disruption)
• Cycle 2–4 weeks, then 2–4 weeks off before repeating

For a detailed breakdown of drop-to-microgram conversions, variant-specific starting doses for NA-Semax and NA-Semax Amidate, and step-by-step nasal technique, see the Semax Dosage and Nasal Protocol guide.

Subcutaneous injection:

• Used when precise dosing is required or nasal tolerance is an issue (chronic rhinitis, deviated septum)
• Typical dose mirrors intranasal: 300–500 mcg per injection
• Bioavailability via injection is higher; some people require dose reduction

Timing considerations: Semax’s stimulating dopaminergic effects mean afternoon or evening dosing frequently disturbs sleep onset. For people already dealing with poor sleep, common in post-Lyme and post-COVID presentations, morning-only administration is the usual advice.

Regulatory context: Semax is an approved medicine in Russia. Outside Russia the EMA and FDA have not authorised it, and the FDA lists it among compounding substances that may present significant safety risks, citing immunogenicity, impurities, and little human safety data.

Who should not use Semax: The Russian label lists hypersensitivity, pregnancy, breastfeeding, acute psychosis, disorders accompanied by anxiety and a history of seizures as contraindications (and, for the 0.1% product, age under 5). Patients on MAOIs or serotonergic medications require caution.

Semax in the Context of Post-Infectious Brain Fog

In post-Lyme and post-COVID patients, neuroinflammation-driven cognitive impairment is one of the most treatment-resistant symptoms. Patients describe it consistently: the words won’t come, thoughts take effort, and the mental fatigue compounds by afternoon. Standard antidepressants and stimulants tend to either miss the mechanism or create tolerance issues.

Semax addresses the problem at a more fundamental level. When neuroinflammation suppresses BDNF — as occurs chronically in these conditions — synaptic pruning accelerates and hippocampal neurogenesis slows. Restoring BDNF signaling through Semax provides the biological substrate for symptomatic recovery to occur, while the anti-inflammatory glial modulation addresses the upstream driver.

In protocols for this population, Semax is commonly combined with BPC-157 (for gut-brain axis support and peripheral inflammation), low-dose naltrexone (for microglial regulation), and targeted mitochondrial support. Semax is rarely a standalone intervention in complex post-infectious cases: it works best as part of a coordinated neurological recovery protocol. Note that combinations of Semax with other unapproved peptides such as BPC-157 have never been tested in trials, and each added compound adds unknowns; see the peptide stacking guide.

What People Report: What Works and What Doesn’t

Sources: the aggregated community data set (Peptide Protocol Wiki, 130 reports), the protocol and side-effect lists on Peptide DB, the Russian product information (RLS), and the Russian studies cited in this article. Doses, including the registered label regimens, are in the protocol table.

Reported to work

• Sharper focus and less mental fog, the most common report, at 200-600 mcg intranasally in the morning.
• A fast onset: users describe effects 15-30 minutes after a nasal dose, peaking at 1-3 hours.
• Easier word-finding and conversation, and more drive for demanding work.
• A mild lift in mood in some users, which fits the dopaminergic effects seen in animal studies.

Mixed or unclear

• Post-viral brain fog after COVID-19 or Lyme disease. People describe benefit, but nearly always as part of a wider protocol, and no trial has tested semax for it.
• NA-Semax and NA-Semax amidate. Users call them stronger and longer-lasting; no published study compares them with standard semax.
• Lasting cognitive gains after a course ends. Most reports describe effects while taking it.

Reported not to work, or disappointing

• Overstimulation, restlessness and mild headaches at higher doses, typically above 600-900 mcg a day and more often with the NA variants.
• Trouble falling asleep when dosed in the afternoon or evening.
• Nasal irritation, which the Russian product information also lists with prolonged use.

What a properly designed trial would need to show: a randomised, placebo-controlled trial outside Russia in people with persistent post-viral cognitive complaints, using a fixed nasal dose for 2-4 weeks, standardised cognitive testing before and after, and a follow-up off treatment.

Side Effects and Safety Profile

Semax has a favorable safety profile from both clinical trial data and its long-term pharmaceutical use in Russia. The most commonly reported side effects are:

• Nasal irritation: Mild and transient, usually resolving within the first week. Occurs in approximately 10–15% of users with standard 0.1% solution.
• Increased vivid dreaming: Related to BDNF upregulation affecting REM sleep architecture. Not pathological; reduces with dose adjustment.
• Mood activation or mild restlessness: Dopaminergic effect; typically dose-dependent and manageable by reducing dose or shifting entirely to morning administration.
• Appetite changes: Some patients note reduced appetite, particularly in the first 1–2 weeks.

Serious adverse events have not been reported in clinical trial data. There are no documented cases of neurotoxicity, organ damage, or endocrine disruption in the published literature. This is consistent with the non-adrenocorticotropic mechanism — Semax does not perturb the HPA axis in the way that ACTH or corticosteroid therapies do.

The absence of long-term (>3 months continuous) human safety data is a real limitation. Cycling protocols rather than continuous administration are the usual answer, which also helps prevent tachyphylaxis. The Russian safety record applies to the pharmaceutical product, not to unregulated “research” versions.

Related Articles

• Selank vs Semax: Which Nootropic Peptide Is Right for You?
• Dihexa: The Peptide for Memory and Cognitive Regeneration
• Post-COVID Brain Fog: A Functional Medicine Approach
• Photobiomodulation for Depression and Brain Fog
• BDNF and the Brain-Gut Axis: How Peptides Support Neural Recovery
• Nootropic Peptides: A Physician’s Guide to Cognitive Enhancement
• Adamax: The Semax Analog With No Published Studies
• Cerebrolysin: What the Stroke and Dementia Trials Actually Show